The global Institutional Review Board Services Market is witnessing robust growth as clinical research, pharmaceutical trials, and regulatory compliance activities expand worldwide. In 2024, the market was valued at approximately USD 1.35 billion, and it is projected to reach USD 2.9 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033. Increasing outsourcing of ethical review processes, rising clinical trial volume, and stringent regulatory frameworks are driving growth across North America, Europe, and Asia-Pacific.

Global Market Size and Year-Over-Year Growth

The Institutional Review Board Services Market has shown consistent growth over the last decade due to rising demand for independent ethical review and compliance management in clinical research. In 2015, the market was valued at USD 680 million. By 2017, it reached USD 805 million, representing a two-year growth of 18.4%.

Year-over-year market expansion is detailed below:

• 2018: USD 890 million

• 2019: USD 970 million

• 2020: USD 1.05 billion

• 2021: USD 1.15 billion

• 2022: USD 1.22 billion

• 2023: USD 1.29 billion

• 2024: USD 1.35 billion

Between 2020 and 2024, the market grew at an average annual growth rate of 6.5–7%, driven by higher clinical trial activity and regulatory complexity.

Historical Market Trends (2015–2024)

Over the last decade, the Institutional Review Board Services Market has expanded alongside global clinical research expenditure. Revenue increased from USD 680 million in 2015 to USD 1.35 billion in 2024, reflecting nearly 100% growth in nine years.

The period from 2018 to 2022 marked accelerated expansion, with the market growing 37% from USD 890 million to USD 1.22 billion, supported by increased outsourcing to independent IRB providers and faster ethical review cycles.

Additionally, the number of registered clinical trials worldwide rose from 183,000 in 2015 to 324,000 in 2024, directly influencing demand for IRB services.

Service Type Segmentation

The Institutional Review Board Services Market includes independent IRBs, local IRBs, and centralized review boards.

Revenue share in 2024:

• Independent IRB services: 55% (~USD 742 million)

• Centralized review boards: 30% (~USD 405 million)

• Local IRB services: 15% (~USD 203 million)

Independent IRBs dominate due to their efficiency in multi-center and global clinical trials. Year-over-year revenue for independent IRBs grew by 8–9% annually between 2020 and 2024.

Year-Over-Year Clinical Trial and IRB Activity

The volume of IRB-reviewed studies has increased consistently. In 2020, independent IRBs reviewed approximately 42,000 studies globally.

Year-over-year activity:

• 2021: 45,800 studies (+9%)

• 2022: 49,200 studies (+7.4%)

• 2023: 52,500 studies (+6.7%)

• 2024: 55,300 studies (+5.3%)

Average review timelines have decreased from 55 days in 2015 to 38 days in 2024, reflecting adoption of digital platforms and workflow automation.

Regional Market Distribution

Regionally, the Institutional Review Board Services Market is concentrated in North America and Europe, with Asia-Pacific emerging as the fastest-growing region.

North America accounted for 48% of global revenue in 2024, approximately USD 648 million. The U.S. dominates due to high clinical trial volume, regulatory requirements, and adoption of independent IRB services.

Europe represents 28% of global revenue, around USD 378 million, with the UK, Germany, and France showing high adoption of centralized review models.

Asia-Pacific contributed USD 205 million in 2024 and is projected to grow at 10.5% CAGR through 2033, fueled by clinical trial expansion in China, India, Japan, and South Korea.

Other regions:

• Latin America: ~USD 77 million (2024)

• Middle East & Africa: ~USD 37 million (2024)

These regions are expected to grow at 7–8% CAGR over the forecast period.

Industry Investments and Technological Adoption

Investment in digital IRB solutions has increased significantly. Between 2020 and 2024, global investment in workflow automation, e-submission platforms, and compliance software exceeded USD 410 million.

Major IRB providers have leveraged AI-based document review, reducing study review times by 25–30%, improving efficiency and throughput. Companies such as WIRB-Copernicus Group and Advarra collectively account for over 60% of global revenue in 2024, indicating high market consolidation.

Government initiatives also support expansion. In 2023, the U.S. FDA allocated approximately USD 12 million to modernize IRB oversight programs, while the European Commission invested USD 7 million in cross-border clinical trial compliance initiatives.

Future Market Forecast (2025–2033)

The Institutional Review Board Services Market is expected to maintain steady growth. Projected market values:

• 2025: USD 1.44 billion

• 2027: USD 1.68 billion

• 2030: USD 2.20 billion

• 2033: USD 2.9 billion

This represents more than 114% growth between 2024 and 2033.

IRB service demand is projected to rise alongside 6.5–7% annual growth in global clinical trial volume, with digital and centralized IRB services capturing a larger market share. The number of studies reviewed by independent IRBs could reach 92,000 annually by 2033.

Data-Driven Conclusion

The Institutional Review Board Services Market has become a vital component of global clinical research infrastructure. Revenue grew from USD 680 million in 2015 to USD 1.35 billion in 2024, driven by outsourcing trends, higher clinical trial activity, and adoption of digital solutions.

With projections indicating growth to USD 2.9 billion by 2033 at a CAGR of 8.3%, the market is set to expand across North America, Europe, and Asia-Pacific. Increased investments in automation, AI-based review platforms, and government-backed regulatory initiatives position the Institutional Review Board Services Market for sustained long-term growth.

Read Full Research Study: https://marketintelo.com/report/institutional-review-board-services-market